title: Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.
abstract: Epstein-Barr Virus (EBV), the first human virus related to oncogenesis, was initially identified in a Burkitt lymphoma cell line in 1964. EBV infects over 90% of the world's population. Most infected people maintain an asymptomatic but persistent EBV infection lifelong. However, in some individuals, EBV infection has been involved in the development of cancer and autoimmune disease. Nowadays, oncogenic potential of EBV has been intensively studied in a wide range of human neoplasms, including Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), etc. EBV encodes a series of viral protein and miRNAs, promoting its persistent infection and the transformation of EBV-infected cells. Although the exact role of EBV in the oncogenesis remains to be clarified, novel diagnostic and targeted therapeutic approaches are encouraging for the management of EBV-related malignancies. This review mainly focuses on the experimental and clinical advances of EBV-associated lymphoproliferative disorders.
authors.affiliation: Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, Shandong, P. R. China.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Geng
authors.affiliation: Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, Shandong, P. R. China ; Department of Diagnostics, Shandong University School of Medicine Jinan 250012, Shandong, P. R. China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
keywords: EBV; lymphoproliferative disorders; microRNA; oncogenisis; signaling pathway; targeted therapy